drugset / Trial / NCT07410377
UCAR T-cell Therapy Targeting CD19/ BCMA(QT-019C) in Patients With Relapse/ Refractory Autoimmune Diseases
Phase 0
Withdrawn
The Affiliated Hospital of Xuzhou Medical University
Shanghai Xiniao Biotech Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells（QT-019C） in With Relapse/Refractory Autoimmune Diseases.
Timeline
- Start
- 2026-03
- Primary completion
- 2027-03
- Completion
- 2028-09
Outcome
Outcome not reported
Stopped: “Internal decision.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QT-019C | Cell therapy | — | Intravenous |